Analysis of complications arising from treatment of advanced kidney cancer by sunitinib and their correction

The own observation of treatment of patients with advanced kidney cancer by sunitinib — the angiogenesis blocker and tyrosine kinases inhibitor medication — is presented. 44 patients having distant metastases of renal cancer underwent therapy. In the course of treatment in the group of favorable and intermediate prognosis ( n = 44), disease-free survival was 13 months, the overall survival rate — 22 months. Analyzed all complications associated with the use of sunitinib. Data obtained allow to recommend sunitinib for the treatment of patients with metastatic renal cell carcinoma with the timely prevention of complications of this treatment.

renal cell cancer, angiogenesis, targeted therapy, adverse events